Business Context and Reporting Period
Company: Pulmatrix, Inc. (PULM)
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2026
Event: Entry into a Material Definitive Agreement (Merger) and related financing transactions.
Pulmatrix, Inc. entered into an Agreement and Plan of Merger with Eos SENOLYTIX, Inc. ("Eos"). Under the agreement, a Pulmatrix subsidiary will merge with Eos, with Eos surviving as a wholly-owned subsidiary of Pulmatrix. The transaction is structured as a tax-free reorganization. Post-merger, Pulmatrix intends to change its name to "Eos SENOLYTIX, Inc."
Key Financial Metrics and Transaction Terms
Ownership Structure (Pro Forma):
- Pre-Merger Eos stockholders: Approximately 94% of the combined company.
- Pre-Merger Pulmatrix stockholders: Approximately 6% of the combined company.
Financing Activities:
- Pulmatrix Financing: Sale of 1,000 shares of Series B Convertible Preferred Stock to an Eos affiliate for gross proceeds of $1,000,000. Conversion price is $2.20 per share. Dividends accrue at 8% per annum (cumulative, payable in stock).
- Eos Financing: Eos entered into agreements for up to $18 million in aggregate gross proceeds via convertible promissory notes ("Eos Notes") and common stock. Initial Bridge Notes of $2,500,000 are expected at the initial closing. Notes accrue interest at 8% (15% upon default).
Debt and Liquidity:
- Pulmatrix is permitted to use up to $250,000 of the net proceeds from its financing for working capital prior to the merger closing.
- The filing does not provide specific current cash balances, total debt, or liquidity metrics for either company as of the filing date.
Material Changes and Governance
Board Composition: Upon closing, the Pulmatrix board is expected to consist of six members: one designated by Pulmatrix and five designated by Eos.
Stockholder Approval: The merger is subject to approval by Pulmatrix stockholders (including a reverse stock split and name change) and Eos stockholders.
Lock-Up: Senotherapeutix, Inc. (sole holder of Eos capital stock) has agreed to a 180-day lock-up period on shares of Pulmatrix common stock received in the merger.
Voting Agreement: The buyer in the Pulmatrix Financing has agreed to vote its shares in favor of the merger proposals.
Guidance, Risks, and Contingencies
Conditions to Closing:
- Approval by stockholders of both companies.
- Nasdaq approval for listing of new shares.
- Effectiveness of the Form S-4 Registration Statement.
- Accuracy of representations and warranties.
Risks and Uncertainties:
- Failure to satisfy closing conditions or obtain regulatory approvals.
- Uncertainty regarding the timing of consummation.
- Risks associated with the combined company's ability to manage expenses and secure additional capital for product development.
- Forward-looking statements regarding clinical trial timelines and commercial potential are subject to significant risks.
Unusual Items: The transaction involves a significant dilution of existing Pulmatrix shareholders (reduced to ~6% ownership) and a change in corporate identity to reflect Eos's business focus.
Investor Verification Checklist
- Form S-4 Filing: Verify the details of the proxy statement/prospectus once filed, as it will contain comprehensive risk factors and financial data.
- Stockholder Vote: Confirm the date and outcome of the Pulmatrix Stockholder Meeting required to approve the merger and name change.
- Financing Closing: Monitor the closing of the $1 million Pulmatrix financing and the $18 million Eos financing to ensure capital availability.
- Nasdaq Listing: Verify Nasdaq's approval of the listing for the shares to be issued in the merger.
- Board Composition: Review the final slate of directors to confirm the shift in control to Eos representatives.